Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257975 | 0.84 | PDE3B (0.42) | TRPA1ALDH1A1HTTRIPK1LMNA | |
| SCHEMBL15471661 | 0.82 | LMNA (0.47) | TRPA1ALDH1A1CYP1A2CYP2A6TAAR1 | |
| SCHEMBL16258055 | 0.81 | CYP17A1 (0.56) | TAAR1LMNACYP17A1CYP11B1CYP11B2 | |
| SCHEMBL16258028 | 0.81 | CYP17A1 (0.56) | TAAR1LMNACYP17A1CYP11B1CYP11B2 | |
| SCHEMBL12154152 | 0.81 | CYP17A1 (0.56) | TAAR1LMNACYP17A1CYP11B1CYP11B2 | |
| SCHEMBL530305 | 0.80 | CNR1 (0.48) | ALDH1A1HTTRIPK1MAOAMAOB | |
| SCHEMBL10240551 | 0.80 | TRPA1 (0.43) | TRPA1ALDH1A1HTTCYP1A2CYP2A6 | |
| SCHEMBL6953517 | 0.80 | SLC6A2 (0.45) | TRPA1CYP1A2CYP2A6TAAR1LMNA | |
| SCHEMBL7712089 | 0.80 | DAO (0.45) | TRPA1ALDH1A1CYP1A2CYP2A6TAAR1 | |
| SCHEMBL8205755 | 0.80 | TRPA1 (0.43) | TRPA1ALDH1A1HTTCYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 871 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | claimed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | claimed |
| EP-4146624-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| EP-4146623-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2022-07-07 | — | — | US | claimed |
| WO-2021224864-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | claimed |
| WO-2021224865-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | claimed |
| WO-2020229968-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2020-11-19 | — | — | WO | claimed |
| EP-2532663-B1 | Naphthalenetetracarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2016-03-16 | — | — | EP | claimed |
| EP-2532663-A1 | Naphthalenecarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2012-12-12 | — | — | EP | claimed |
| US-6677452-B1 | PREPARED BY REACTING AMINE WITH PYRIDINE SUBSTITUTED WITH HALOGEN AT POSITION 6 AND WITH CARBOXY OR SULFONYL GROUP AT ANOTHER POSITION TO FORM AMIDE OR SULFONAMIDE, DISPLACING HALOGEN WITH DESIRED DIAMINE | LION BIOSCIENCE AG (DE) | 2004-01-13 | — | — | US | claimed |
| EP-1218343-A4 | PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2003-06-18 | — | — | EP | claimed |
| EP-1218343-A1 | PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001025203-A1 | PYRIDINE CARBOXAMIDE OR SULFONAMIDE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-12 | — | — | WO | claimed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024143514-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | 中外製薬株式会社 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024138211-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-1990004623-A1 | MATRIX LIQUID CRYSTAL DISPLAY | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-05-03 | — | — | WO | disclosed |
| EP-0285324-A1 | Preparation of substituted fluorobenzenes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-10-05 | — | — | EP | disclosed |
| US-4754084-A | PYROLYSIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348387-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | TRPA1 3778/4885ALDH1A1 3200/4885HTT 1072/4885 |
| US-20220213058-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | TRPA1 3778/4885ALDH1A1 3200/4885HTT 1072/4885 |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | TRPA1 3778/4885ALDH1A1 3200/4885HTT 1072/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | TRPA1 4791/4885ALDH1A1 477/4885HTT 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.